Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Accured Expenses (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Change in Accured Expenses for 14 consecutive years, with $958000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 13.46% to $958000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 52.65% increase, with the full-year FY2025 number at $1.8 million, up 52.65% from a year prior.
  • Change in Accured Expenses was $958000.0 for Q4 2025 at Niagen Bioscience, down from $1.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.6 million in Q1 2022 to a low of -$1.8 million in Q2 2024.
  • A 5-year average of $320350.0 and a median of $860000.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 58566.67% in 2021, then surged 1756.67% in 2023.
  • Niagen Bioscience's Change in Accured Expenses stood at $150000.0 in 2021, then soared by 287.33% to $581000.0 in 2022, then tumbled by 48.36% to $300000.0 in 2023, then soared by 269.0% to $1.1 million in 2024, then dropped by 13.46% to $958000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Change in Accured Expenses are $958000.0 (Q4 2025), $1.3 million (Q3 2025), and -$1.7 million (Q2 2025).